Background: Although atopic dermatitis (AD) often starts in early childhood, detailed tissue profiling of early-onset AD in children is lacking, hindering therapeutic development for this patient population with a particularly high unmet need for better treatments. Objective: We sought to globally profile the skin of infants with AD compared with that of adults with AD and healthy control subjects. Methods: We performed microarray, RT-PCR, and fluorescence microscopy studies in infants and young children (<5 years old) with early-onset AD (<6 months disease duration) compared with age-matched control subjects and adults with longstanding AD. Results: Transcriptomic analyses revealed profound differences between pediatric patients with early-onset versus adult patients with longstanding AD in not only lesional but also nonlesional tissues. Although both patient populations harbored T H 2-centered inflammation, pediatric AD also showed significant T H 17/T H 22 skewing but lacked the T H 1 upregulation that characterizes adult AD. Pediatric AD exhibited relatively normal expression of epidermal differentiation and cornification products, which is downregulated in adults with AD. Defects in the lipid barrier (eg, ELOVL fatty acid elongase 3 [ELOVL3] and diacylglycerol o-acyltransferase 2 [DGAT2]) and tight junction regulation (eg, claudins 8 and 23) were evident in both groups. However, some lipid-associated mediators (eg, fatty acyl-CoA reductase 2 and fatty acid 2-hydroxylase) showed preferential downregulation in pediatric AD, and lipid barrier genes (FA2H and DGAT2) showed inverse correlations with transepidermal water loss, a functional measure of the epidermal barrier. Conclusions: Skin samples from children and adult patients with AD share lipid metabolism and tight junction alterations, but epidermal differentiation complex defects are only present in adult AD, potentially resulting from chronic immune aberration that is not yet present in early-onset disease. (J
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, affecting up to 20% of children and 7% to 10% of adults. [1] [2] [3] A strong immune infiltrate and impaired skin barrier are thought to characterize the disease, 4 but their initial sequence and exact interplay are still not fully understood. 5 AD usually begins before age 5 years, with approximately 60% of patients experiencing disease onset within the first year of life. 2 However, skin data are largely limited to samples from adolescents and adults with years to decades of disease activity, [6] [7] [8] [9] raising the possibility of considerable differences compared with early AD in infants. 10, 11 In a recent study our group assessed selected inflammatory and barrier markers in pediatric patients less than 5 years of age within 6 months of disease onset. 10 Using immunohistochemistry and quantitative RT-PCR, we found T H 2 activation, as in adult AD skin. However, we also noted strong upregulation of T H 17/IL-23 responses and antimicrobial peptide (AMP) mRNA expression in young children 10 similar to levels seen in psoriasis and in contrast to the relatively reduced AMP expression in acute and chronic adult AD. 12 In addition, filaggrin (FLG), a skin barrier protein that has been implicated as a central player for AD development because of cytokine-mediated downregulation (in addition to loss-of-function mutation in a minority of AD patients) 13, 14 was still present at normal levels in pediatric early-onset AD. Despite intact FLG expression, a barrier defect was present in early-onset AD, as reflected by high levels of transepidermal water loss (TEWL), 10 a discrepancy that remained unexplained.
Thus a global profiling of AD initiation in both lesional and nonlesional skin compared with skin tissue from both age-matched control children and adults with chronic AD of similar severity is lacking. This global molecular profiling was performed to gain better insight into pathogenic mechanisms that are potentially operative during initial AD. We found that early disease initiation has substantial differences compared with adult AD, with strong T H 2-and T H 17/T H 22-centered inflammation but lacking T H 1 activation and terminal differentiation abnormalities, as seen in adults.
METHODS

Patients' characteristics
Nineteen children 3 months to 5 years of age (mean age, 1.3 years) with AD onset within the previous 6 months and moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) 10 were included in analyses (Table I) . 15 Parents signed institutional review board-approved consent forms before study inclusion. No heterozygous FLG mutations (R501X and 2282del4 allele) were found in any pediatric patient with AD. The FLG mutation status for 2282del4 was unavailable for 1 patient because of an inadequate sample. Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. TEWL was measured at biopsy sites by using a Tewameter (Courage and Khazaka GmbH, Cologne, Germany; Table I ). Lesional and nonlesional 4-mm biopsy specimens from affected popliteal and unaffected buttock skin, respectively, were obtained. All biopsy specimens were from chronic lesions present for more than 72 hours. 11 Pediatric control skin was collected during routine surgical procedures from a group of 18 healthy subjects matched for age, sex, and ethnicity without personal/familial atopy. Lesional and nonlesional tissues from adults with AD (n 5 20; age range, 18-73 years) with similar disease severity (SCORAD score: mean, 62.4; range, and matched control skin (n 5 11; age range, 38-57 years) from previously reported cohorts [16] [17] [18] were included as comparators (Table I) .
Visualization of skin lipid deposition
Fresh cryostat sections were stained with Nile red solution (500 mg/mL) in acetone, and images were acquired by using appropriate filters of the Zeiss Axioplan 2 (LSM 510; Carl Zeiss Microimaging, Thornwood, NY), as previously reported.
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Quantitative RT-PCR and microarray analysis RNA was extracted for RT-PCR with EZ-PCR Core Reagents (Life Technologies, Grand Island, NY), as previously described. 20 Expression levels were normalized to human acidic ribosomal protein. HGU133Plus2.0 microarrays (GSE#107361; Affymetrix, Santa Clara, Calif) were used, as previously described. 11, 20, 21 
Statistical analyses
Statistical analyses were performed with R software (www.R-project.org), with respective packages available through Bioconductor (www.bioconductor. org). Standard quality control metrics and the R package microarray QualityControl were used for microarrays, as previously described. 20 Images were scrutinized for artifacts by using Harshlight. 22 Expression measures were obtained by using the GCRMA algorithm. 23 Batch effects were adjusted with Combat. 20, 24 Unsupervised hierarchical clustering with Euclidean distance and McQuitty agglomeration were applied for heat maps. 23 Probe sets with expression values of greater than 3 were kept for analyses. Data from microarray experiments were log 2 transformed before analyses with a linear mixed-effects model. For AD samples, age category and tissue type (lesional, nonlesional, or control tissue) were used as fixed factors, with a random effect for sex and race/ethnicity. Fold changes were estimated, and hypothesis testing was conducted by using contrasts in the R limma package linear model framework. 20 The Benjamini-Hochberg procedure was used to adjust P values from paired t tests for multiple hypotheses. For RT-PCR, human acidic ribosomal protein-normalized expression levels were log 2 -transformed before analyses. For each marker, mixed-effect models were fit with age category and tissue type as fixed factors and a random effect for sex and race/ethnicity.
RESULTS
Study patients
Nineteen children less than 5 years old with early-onset AD (<6 months disease duration) and 18 age-matched pediatric control subjects, as well as a group of 20 adults with AD with comparable disease severity and 11 age-matched adult control subjects, were studied.
The pediatric AD skin phenotype shows substantial differences from longstanding disease in adults A principal component analysis adjusted for batch effects showed distinct grouping of nonlesional, lesional, and healthy skin that differed from that in adult subjects (Fig 1, A) . Using criteria of fold change of greater than 2 and a false discovery rate of less than 0.05, we assessed differentially expressed genes (DEGs) for lesional versus nonlesional AD (Fig 1, B) and lesional AD versus healthy control tissues (Fig 1, C) . The pediatric lesional versus nonlesional comparison included 788 DEGs (424 upregulated and 364 downregulated; Fig 1, B) and 3078 DEGs in lesional AD versus healthy control tissues (1168 upregulated and 1910 downregulated; Fig 1, C) . Only 22.6% (lesional vs nonlesional tissues) and 30.3% (lesional vs healthy control tissues) of DEGs in pediatric patients with AD were shared with the adult AD profile. Although key T H 2 and T H 22 genes implicated in AD pathogenesis 4, 25 were among the common AD profile (Fig 1, B and C, and see Table E1 in this article's Online Repository at www.jacionline.org) across adults and children (ie, CCL17/CCL18/CCL22/IL-4 receptor among T H 2 and S100A7/S100A8/S100A9/S100A12 among T H 22 genes), other genes associated with the adult AD profile, 13, 18, 26 including IFNGR1 (T H 1), CCL20 (T H 17), and FLG (barrier), showed different regulation in children and adults (see Table E1 ).
Immune gene expression in patients with early pediatric versus those with adult AD Given that emerging AD treatments are designed to target specific inflammatory mediators, it is imperative to understand how immune circuits in children differ from those in adults. As a result, we compared the immune phenotype of lesional and nonlesional skin in children versus adults with AD by using a predefined immune gene subset, 16, 20, 27 as displayed in a heat map sorted by using hierarchical clustering (Fig 2) . Healthy pediatric and adult control subjects largely showed similar mRNA expression levels of immune markers, except for the innate cytokines IL-6, IL-1b, and CXCL8/IL-8 and the T H 17-associated CCL20, peptidase inhibitor 3 (PI3)/elafin, IL-23A/IL-23p19, CXCL2, and signal transducer and activator of transcription (STAT) 3, levels of which were increased in children (Fig 2) . The IFN-g-associated cytokine IL-18, the IgE receptor subunit FcεRIA, and the T H 2-associated cytokine IL-33 were among the significantly decreased mediators in pediatric versus adult control skin (Fig 2) . Pediatric patients already showed significant upregulation of inflammatory markers in their nonlesional skin (Fig 2) . Impressive increases in nonlesional pediatric AD skin (compared with adults) were seen in T H 17/T H 22 products, including S100A7, S100A8, S100A9, and S100A12, as well as the T H 17-and T H 2-associated cytokine IL-19. 28, 29 Nonlesional pediatric AD lacked upregulation of several IFN-g markers, including STAT1, IFNGR1, and interferon regulatory factor 1 (IRF1) and some T H 2-polarizing chemokines (CCL17, CCL18, and CCL26) in contrast to nonlesional adult AD. The trend of stronger upregulation of T H 17/T H 22 markers in nonlesional pediatric AD was also seen in lesional pediatric AD compared with adult AD (S100A7, S100A8, S100A9, S100A12, CXCL1, IL-22, and IL-26), as visualized in a cluster marked by a yellow box (Fig 2) . In fact, numerous T H 17/T H 22-associated mediators (lipocalin 2 [LCN2], CCL20, IL23A/IL-23p19, IL-36A, IL-36B, IL-36G, and IL-36RN) and IL-19 were upregulated solely in pediatric lesions (Fig 2, green box) . Conversely, a cluster containing several T H 1-associated mediators (CXCL9, CXCL10, STAT1, IFNGR1, and IL12RB2) showed stronger upregulation in adult AD lesions (Fig 2, 
Pediatric AD shows upregulation of IL-17-and TNF-a-regulated genes
Because of the strong T H 17 skewing in pediatric AD, which is classically found in adult psoriasis, 31 we evaluated AD expression levels of a subset of genes previously shown to be synergistically and/or additively regulated in vitro by IL-17 and TNF-a, 32 mimicking the psoriasis inflammatory milieu. 31 As shown in Only a small cluster was upregulated exclusively in adult AD (within the blue box). To further confirm this trend, we performed quantitative RT-PCR on genes previously described as being highly upregulated in psoriasis but not in adult AD tissues, including TNF-a, 33 CCL7, 34 KYNU, 35 IL-36B, 36 IL-36G, 37 and epiregulin (EREG). 38 Indeed, these ''psoriasis hallmark'' markers showed significantly higher expression in early-onset pediatric AD compared with adult AD (Fig 4, A-F) . Because of these differences, we assessed our pediatric tissues using a molecular disease classifier that had been validated for differentiating adult AD and psoriasis (Fig 4, G and H) . 7 This classifier evaluates levels of inducible nitric oxide synthase (ie, nitric oxide synthase 2 [NOS2]) and CCL27, with increased NOS2 levels characterizing psoriasis and normal or increased CCL27 levels associated with AD. 7, 39 Our pediatric samples clearly classified as AD, similar to their adult counterparts (Fig 4, G and H) , confirming the clinical AD diagnosis despite the marked differences in the immune phenotype of children compared with adults with AD.
Barrier genes
In addition to aberrant immune activation, epidermal barrier impairment is thought to be a central pathogenic mechanism in 15 AD initiation, including allergic sensitization through the skin. 13, 14 The skin barrier is critically regulated by keratinocyte differentiation, including expression of genes of the epidermal differentiation complex (EDC), which includes genes encoding cornified envelope proteins. 19, 40 Other important barrier mediators are lipid metabolism components 9, 19, [41] [42] [43] and proteins regulating tight and adherens junctions (eg, claudins [CLDNs] and cadherins). 44, 45 Differences in genomic expression of a predefined gene subset of barrier genes downregulated in adult AD 16, 19, 27, 41, 46 were assessed in our AD groups compared with their respective control subjects. Markers with comparable expression levels in pediatric and adult healthy control samples are summarized in Fig 5 within (1) blue, (2) red, and (3) green boxes for genes preferentially downregulated in (1) pediatric AD, (2) both pediatric and adult AD, and (3) adult AD, respectively (Fig 5, A) . Multiple genes encoding EDC/terminal differentiation proteins were significantly downregulated in nonlesional and, even more so, in lesional adult, but not in pediatric AD (Fig 5, A, gene names in orange letters); in contrast, several lipid-associated markers (Fig 5, A, gene names in green letters) showed significant reductions in both pediatric and/or adult skin.
Among important EDC and other differentiation-related genes that exhibited normal or near-normal expression in pediatric AD, but were significantly downregulated in adult AD, were FLG, loricrin (LOR), sciellin (SCEL), and PSORS1C2, 47 as well as the late cornified envelope (LCE) proteins LCE1B/LCE1E/ LCE2B (Fig 5, A) . Conversely, annexin A6 (ANXA6), a calcium-dependent membrane and phospholipid-binding protein previously reported to be upregulated in adult AD and decreased in psoriasis, 48 was significantly downregulated in our pediatric patients (Fig 5, A) . Levels of several adhesion molecules (CLDNs and cadherins) were decreased in both pediatric and adult AD, including CLDN8 and CLDN23, although to a greater extent in adult AD (Fig 5, A) . CLDN1, which was previously shown to be reduced in adult AD and inversely correlated with serum IgE levels and eosinophil counts, 49 showed even stronger downregulation in pediatric AD.
Several lipid-related genes were also downregulated in pediatric AD. ELOVL fatty acid elongase 3 (ELOVL3), a lipid-associated marker previously reported to be decreased in adult AD, 41 was also significantly downregulated in pediatric AD (Fig 5, A, within the red box). ELOVL3 encodes a protein involved in elongation of long-chain fatty acids that is essential in limiting TEWL. 41 Another lipid mediator, diacylglycerol o-acyltransferase 2 (DGAT2), was also significantly downregulated in both adult and pediatric patients with AD. DGAT2 knockout mice develop severe skin permeability barrier dysfunction and die from increased dehydration. 50 Other lipid barrier components, such as fatty acyl-CoA reductase 2 (FAR2) and fatty acid 2-hydroxylaxe (FA2H), 41 showed preferential downregulation in pediatric AD (Fig 5, A) .
Using RT-PCR, we assessed selected barrier-associated markers, 19, 41, 51 such as FAR2, peroxisome proliferator activated receptor gamma (PPARG), and LCE2B, to confirm microarray results (Fig 5, B-D) . Our data indicate that EDC/terminal differentiation downregulation, a phenomenon previously considered a hallmark of AD, 52, 53 was largely absent in our pediatric samples, whereas lipid and tight junction alterations characterized both adult and pediatric AD.
Further evidence of skin lipid defects in lesional and nonlesional pediatric AD
The stratum corneum serves as a platform for a neutral lipid enriched extracellular matrix. 54 This hydrophobic lipid matrix (Fig 1, B) or matched healthy control skin (Fig 1, C) .
FIG 2.
Immune gene regulation in tissues from pediatric and adult patients with AD. Heat maps of immune-associated DEG subsets, as calculated by a fold change (FCH) of greater than 2 and false discovery rate (FDR) of less than 0.05 by using microarray data. Samples are sorted by means of hierarchical clustering: red, greater expression; blue, lower expression. Group comparisons (FCHs) are indicated. 1FDR-adjusted P < .1; *FDR-adjusted P < .05; **FDR-adjusted P < .01. HC, Age-matched healthy control subject; LS, lesional; NL, nonlesional. Red box, Upregulation in pediatric and adult patients with AD; yellow box, stronger upregulation in pediatric versus adult patients with AD; blue box, stronger upregulation in adult patients with AD; green box, preferential upregulation in pediatric patients with AD.
FIG 3.
Heat map of TNF-a-and/or IL-17-regulated DEG subsets, as calculated by a fold change (FCH) of greater than 2 and a false discovery rate (FDR) of less than 0.05 based on microarray data. Samples are sorted by using hierarchical clustering: red, greater expression; blue, lower expression. Group comparisons (FCHs) are indicated. 1FDR-adjusted P < .1; *FDR-adjusted P < .05; **FDR-adjusted P < .01. HC, Age-matched healthy control subject; LS, lesional; NL, nonlesional; HC, age-matched healthy control subject. Yellow box, Stronger upregulation in pediatric than adult patients with AD; green box, tendency of upregulation in pediatric and downregulation in adult patients with AD; blue box, upregulation only in adult patients with AD. ) of pediatric and adult skin with matched healthy control subjects of disease markers previously reported to be strongly increased in psoriasis (A-F) and of genes previously described by Eyerich et al in a psoriasis/AD disease classifier (G and H): *P < .05, **P < .01, and ***P < .001. Asterisks above error bars indicate a significant change from age-matched healthy control tissue; asterisks above lines refer to respective comparisons. HC, Healthy control subject; LS, lesional AD; NL, nonlesional AD; ped, pediatric.
enables the skin barrier to block the movement of water and electrolytes. 54 Because multiple lipid-associated mediators were downregulated in both pediatric and adult AD, we visualized stratum corneum lipids using Nile red staining. 55, 56 Although we observed a regularly layered staining pattern in the stratum corneum of healthy control skin (Fig 6, A, arrows) , lipid layers were absent in both lesional and nonlesional AD pediatric skin (Fig 6, B and C, arrowheads) as in adult AD (Fig 6, D-F) . 19 These lipid alterations further explain the increases in TEWL, representing a functional barrier defect, in early-onset pediatric AD skin (Table I ).
IL-26 shows a strong positive correlation with TEWL in pediatric AD
We next assessed the correlation of differentially regulated genes in pediatric AD tissues with TEWL, a functional measure of poor skin barrier integrity (see Table E2 in this article's Online Repository at www.jacionline.org). 57 The strongest positive correlation was found for IL-26 (Fig 7, A) , an IL-20 family cytokine that signals through STAT1 and STAT3 and is strongly expressed by T H 17 cells. 58 IL-26 levels were increased significantly in nonlesional and lesional pediatric AD and, to a lesser extent, in lesional adult AD skin (Fig 2, within yellow  box) . Similarly, STAT3 expression (increased in pediatric vs adult AD, Fig 2, just below the green box) positively correlated with TEWL (Fig 7, B) , whereas lipid-associated measures downregulated in pediatric AD (eg, DAT2 and FA2H) 41, 50 showed negative correlations with TEWL (Fig 7, C and D , and see Table E2 ). These data further corroborate the notion that immune activation and skin lipid defects negatively affect the skin barrier in early-onset AD.
We also evaluated correlations between levels of total serum IgE and various skin markers. Serum IgE levels were positively correlated with some T H 2-associated mediators (TSLP and CCL27) and phosphodiesterase 4B (PDE4B), which is targeted by crisaborole, 59, 60 and negatively associated with barrier markers (ie, DGAT2 [lesional], FAR2 and CLD10 [nonlesional]; see Fig E1 and Table E3 in this article's Online Repository at www.jacionline.org).
DISCUSSION
This is the first study to broadly characterize immune and barrier properties in skin biopsy specimens from infants with recent-onset AD. Skin sensitization during early-onset pediatric AD is considered the initiating step of the atopic march, 61 and its characterization might help develop approaches that can prevent atopic diathesis through either restoration of barrier integrity or early immune modulation. 62 The pattern of immune activation shown by our data corroborates and expands the previous findings from our group based on analysis of a limited series of markers (ie, T H 2-centered inflammation in both adult and pediatric patients with AD, with stronger T H 9, T H 17, and T H 22 activation and lack of IFN-g/Th1-associated inflammation in pediatric versus adult patients with AD). 10 Importantly, we also explored the lack of downregulation of FLG expression because we still noted a functional barrier defect in our early-onset pediatric cohort, which was reflected by increased TEWL in lesional and nonlesional AD when compared with healthy children. To date, defects in FLG caused by downregulation by T H 2 cytokines 63 or loss-of-function mutations, with the latter being found in 10% to 50% of patients with AD, 64 have been regarded as central to the barrier impairment seen in AD. FLG has been shown to be important for maintenance of epidermal homeostasis, 65, 66 and loss-offunction mutations in the FLG gene significantly increase the risk for AD and atopic diathesis. [67] [68] [69] Lack of FLG has been demonstrated to disturb keratinocyte maturation and differentiation [70] [71] [72] and to negatively affect lipid composition 73 and natural moisturizing factors, 74, 75 and to increase skin permeability. 76 Common FLG mutations were absent in our patients, 10 and we confirmed our prior findings of intact FLG expression in early-onset AD tissues using RT-PCR and immunohistochemistry staining. 10 Similarly, other EDC/terminal differentiation mediators, including loricrin (LOR), the main component of the cornified envelope, 77 were downregulated to a very small extent in pediatric versus adult AD skin, despite the high TEWL levels in children with AD. These results challenge the current dogma that EDC/terminal differentiation components are key pathogenic factors for the elicitation of AD. 52, 53 Because IL-4 and IL-13 have been shown to decrease FLG expression levels in vitro, 63 it was surprising that the strong T H 2 polarization in pediatric patients with AD does not reduce expression of FLG and other EDC/terminal differentiation genes. Although earlier reports showed that IL-4 and IL-13, but not IFN-g, inhibit FLG expression during keratinocyte differentiation in vitro, 63, 78 more recent studies demonstrated that IFN-g is also able to downregulate FLG, 79, 80 as well as reduce ceramides and long-chain fatty acids, 81 in human keratinocytes, potentially contributing to the accentuated differentiation abnormalities seen in adults versus children with AD. 79, 81, 82 Our data would suggest that abnormal barrier function in the skin of pediatric patients with AD does not reflect reduced differentiation but rather is suggestive of defects in tight junction proteins and lipid deposition, with the latter demonstrated by the virtually absent Nile red staining of the stratum corneum of lesional and nonlesional tissues from both pediatric and adult patients with AD. Since removal of stratum corneum lipids by using a gentle lipid solvent is sufficient to vastly abrogate the permeability barrier, 83, 84 the defect in the lipids within the stratum corneum may be the major contributor for the TEWL abnormalities observed in early-onset pediatric AD, as also suggested by the reductions in several genes involved in regulation of barrier lipids in pediatric AD skin. Evaluation of lipid profiles by using mass spectrometry in early pediatric AD will thus be important to further delineate deficits in specific epidermal lipids. Both IL-17 [85] [86] [87] (increased in pediatric, but not adult AD skin) and T H 2 cytokines [88] [89] [90] [91] were reported to negatively affect expression of tight junction components and permeability, as well as expression of CLDNs (1/8/23), which are key components of tight junctions, which were downregulated in both adult and pediatric AD tissues. Tight junction deficits might be particularly relevant in allowing permeation of larger xenobiotes, particularly when the overlying lipid-based barrier is also defective. plasmacytoid dendritic cells, potentially triggering skin inflammation. 58 IL-26 is also strongly upregulated in psoriasis and mycosis fungoides. 93 In contrast to IL-17, IL-26 expression is insensitive to inhibition by IL-4, 93 potentially explaining its high levels in our pediatric cohort despite strong T H 2 activation.
Levels of IFN-g, which is considered a hallmark of chronic but not acute adult AD, 94 were not increased in early-onset pediatric skin, even though the pediatric AD lesions were chronic lesions (ie, >72 hours in duration). Consistently, pediatric lesions showed similar acanthosis to the skin of adult patients with chronic AD. 10 In fact, some mediators of pediatric T H 1 cytokine expression are reduced in blood from pediatric patients with AD versus that from healthy subjects, such as IFN-g 1 cutaneous lymphocyte antigen (CLA) 1 skin-homing CD4 1 T cells. 95 Despite this lack of IFN-g responses, early-onset AD shares molecular features with psoriasis, as reflected by the significant increases in TNF-a/IL-17-associated markers, including classic psoriasis markers, such as EREG, KYNU, and antimicrobial peptides. 10, 12, 35, 38 Nevertheless, a molecular psoriasis/AD disease classifier consisting of CCL27 and inducible nitric oxide synthase (NOS2) 7, 39 clearly categorized our pediatric samples as AD, similar to their adult AD counterparts. Interestingly, adult patients with AD showed progressive CCL27 increases from nonlesional to lesional AD, whereas in pediatric samples CCL27 levels were greater in patients with nonlesional versus lesional AD, which might be explained by the fact that increased IL-17 can downregulate CCL27 expression. 39, 96 CCL27 levels also positively correlated with serum IgE levels, which showed negative correlations with some barrier products, but these data were derived from a limited set of patients with available IgEs and require confirmation in larger studies.
This study sheds new light on the unique properties of early onset pediatric AD skin, highlighting the role of lipid abnormalities and IL-17/TNF-a-dependent inflammation, including expression of IL-26, as distinct features from adult AD skin. IFN-g responses are likely to contribute to barrier defects, particularly those involving EDC/terminal differentiation, which predominate in adult AD lesions after years to decades of disease chronicity. The phenomenon of increased T H 1 and decreased T H 17 immune activation in adults with chronic AD may be rooted in mutual antagonism of T H 17 and IL-12/T H 1 responses, as observed in several model systems. 97, 98 However, whether the observed immune changes are truly causative of the pathology in patients with AD and the exact mechanism by which the transition from the early-onset pediatric to adult AD phenotype occurs or whether any of these mechanisms are involved in the determination of whether a child will outgrow AD or have persistent disease into adulthood remain to be elucidated. Also, ethnic differences among pediatric populations might influence the immune phenotype, as demonstrated in adult patients with AD, 18 necessitating further investigation in larger pediatric cohorts. Similarly, the pediatric AD phenotype might be different in the setting of hierarchical clustering: red, higher expression; blue, lower expression. Group comparisons (FCHs) are indicated. 1FDR-adjusted P < .1; *FDR-adjusted P < .05; **FDR-adjusted P < .01. HC, Age-matched healthy control subject LS, lesional; NL, nonlesional. Boxes indicate preferential downregulation in pediatric patients with AD (blue), both pediatric and adult patients with AD (red), and adult patients with AD (green). B-D, RT-PCR analysis of selected barrier markers. *P < .05, **P < .01, and ***P < .01. Asterisks above error bars indicate significant difference from age-matched healthy control tissue. HC, Healthy control subjects; NL, nonlesional AD; LS, lesional AD; ped, pediatric. = J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 FLG loss-of-function mutations, which show type 1 interferon-mediated stress response, although in adolescents. 9 Nevertheless, the distinct phenotype of early-onset pediatric AD highlighted by the present study might have profound implications for future targeted treatment approaches in this patient group.
Clinical implications: Numerous differences in immune (T H 17/ T H 22/T H 1 responses) and barrier abnormalities (epidermal terminal differentiation) between early-onset pediatric AD versus longstanding adult AD might necessitate different targeted treatment approaches for these age groups. 
